Every time you eat, your pancreas releases insulin, which docks onto the insulin receptor on cell surfaces and triggers a cascade that pulls glucose from your blood into cells for energy. PTP1B¹¹ PTP1B
Protein Tyrosine Phosphatase 1B — the protein encoded by PTPN1 — is the enzyme that turns this signal off by removing phosphate groups from the activated receptor. It acts as a critical brake on insulin signaling: too much PTP1B activity means cells stop responding to insulin faster than they should, effectively causing insulin resistance at the molecular level.

PTP1B also dephosphorylates the leptin receptor, the central hunger-regulating signal. A cell with elevated PTP1B activity is simultaneously less responsive to insulin (glucose handling) and less responsive to leptin (satiety signaling), creating a dual vulnerability to both metabolic disease and weight dysregulation.

The Mechanism

rs941798 sits in an intron of PTPN1 on chromosome 20q13 and does not itself change the PTP1B protein. Instead, it serves as a tag for a haplotype block²² haplotype block
a stretch of DNA inherited together as a unit, typically 50-200 kb, where nearby variants are correlated due to limited historical recombination spanning the entire PTPN1 gene (introns 1-8, ~100 kb) that modulates how much PTP1B is expressed. G-allele carriers appear to produce more PTP1B enzyme, which more aggressively terminates insulin receptor signaling after activation.

The G allele of rs941798 is strongly correlated with rs2426159 (a neighboring intronic SNP) and both tag the same risk haplotype. When researchers tested all SNPs across the PTPN1 locus, the association with metabolic traits was not confined to any single variant but ran across the entire haplotype block — a classic pattern for a regulatory variant whose effect spreads to all SNPs in linkage disequilibrium.

The Evidence

Multiple independent research groups have investigated the PTPN1 intronic haplotype:

Bento et al. (Diabetes, 2004)³³ Bento et al. (Diabetes, 2004) typed 23 noncoding PTPN1 SNPs in two independently recruited Caucasian case-control sets. SNPs spanning introns 1-8 were consistently associated with type 2 diabetes across both datasets (p = 0.002–0.038), with odds ratios of approximately 1.3 and a population-attributable risk of 17-20%.

Palmer et al. (Diabetes, 2004)⁴⁴ Palmer et al. (Diabetes, 2004) in the IRAS Family Study found that all 20 PTPN1 SNPs within the haplotype block were associated with the insulin sensitivity index (Si) in 811 Hispanic Americans (p = 0.003–0.044), with protective haplotypes associated with higher Si (better insulin sensitivity) and risk haplotypes with lower Si and higher fasting glucose.

Cheyssac et al. (BMC Med Genet, 2006)⁵⁵ Cheyssac et al. (BMC Med Genet, 2006) studied 1,274 French T2D cases and 1,047 controls. rs941798 and the correlated rs2426159 showed "multiple consistent associations" across metabolic traits in 736 normoglycaemic subjects: higher fasting insulin (p = 0.04), higher HOMA-B (p = 0.04), elevated lipid markers (p = 0.02–0.04), and increased systolic blood pressure in risk-allele homozygotes (p = 0.03).

However, the association picture is incomplete. Florez et al. (Diabetes, 2005)⁶⁶ Florez et al. (Diabetes, 2005) found no significant association between PTPN1 tag SNPs or haplotypes and T2D in 7,883 subjects — the largest study to date on this question. This negative replication in a well-powered study tempers the evidence and is the main reason rs941798 is classified at the moderate evidence level rather than strong. The associations seen in smaller studies may partly reflect population-specific linkage disequilibrium patterns, insufficient statistical power in the replication, or genuine heterogeneity of effect across ancestries.

Practical Actions

For G-allele carriers, the actionable implication is that PTP1B may be relatively more active, blunting insulin and leptin receptor signaling more aggressively. This does not mean diabetes is inevitable, but it does mean the molecular thermostat for insulin sensitivity is set at a less favorable baseline.

Dietary carbohydrate quality matters more for those with impaired insulin signaling: low-glycemic index carbohydrates produce smaller, more sustained glucose excursions that require less compensatory insulin secretion. Reducing refined carbohydrate load lowers the demand on insulin receptor signaling.

Berberine, a plant alkaloid primarily derived from Berberis species, has been shown in multiple clinical trials⁷⁷ multiple clinical trials to improve insulin sensitivity through multiple mechanisms including AMPK activation. Some research suggests it may also reduce PTP1B expression. At 500 mg twice daily with meals, berberine lowers fasting glucose and HbA1c comparably to metformin in several head-to-head trials.

Fasting glucose and HbA1c monitoring once or twice yearly provides early detection of deteriorating glucose control — actionable before symptoms appear.

Interactions

rs941798 sits in the same metabolic signaling node as TCF7L2 (rs7903146), which governs insulin secretion from beta cells. PTPN1 controls insulin receptor sensitivity; TCF7L2 controls how much insulin is released. Carrying risk alleles at both loci creates a compounded vulnerability: less insulin secreted (TCF7L2) and less effective use of the insulin that is released (PTPN1).

The leptin-signaling connection links rs941798 to appetite regulation. PTP1B terminates both insulin and leptin receptor signaling. Variants in LEP (leptin) or LEPR (leptin receptor) combined with elevated PTPN1 activity could amplify leptin resistance and reduce the effectiveness of satiety signaling.

Presenilin-1¹¹ Presenilin-1
Encoded by PSEN1 on chromosome 14; forms the catalytic subunit of the gamma-secretase complex, responsible for cleaving the amyloid precursor protein (APP) within neuronal membranes mutations account for the largest share of familial early-onset Alzheimer's disease (EOFAD), with over 300 pathogenic variants identified across the gene. The M233V substitution is among the most severe — documented cases develop cognitive symptoms as early as age 25, with a typical onset range of 25–32 years. No population-wide allele frequency exists because the variant is so rare it was absent in both the PAGE Study (78,692 samples) and the ALFA cohort (660 samples); it is detected only in affected families and sporadic de novo cases.

The Mechanism

PSEN1 encodes the catalytic aspartyl protease component of the gamma-secretase complex²² gamma-secretase complex
A four-protein membrane complex that cleaves type I transmembrane proteins within the lipid bilayer; substrates include APP and Notch. In normal processing, gamma-secretase cleaves APP at multiple sites to produce a mixture of Aβ peptides, predominantly the shorter Aβ40 form. The M233V substitution (c.697A>G) disrupts cleavage geometry at the active site of PSEN1, shifting the Aβ42/Aβ40 ratio markedly upward. Aβ42 is far more prone to aggregation than Aβ40 and seeds amyloid plaques preferentially. Functional studies confirm M233V alters both the Aβ49→40 and Aβ48→38 cleavage lines, simultaneously increasing Aβ42 production and decreasing Aβ38 production in a pattern consistent with the most aggressive PSEN1 mutations.

Methionine 233 sits within transmembrane domain 5 of PSEN1. The homologous position in PSEN2 (M239V) is also pathogenic, indicating that this methionine residue is conserved and structurally critical for correct APP positioning at the active site. The result is a relentless, lifelong increase in Aβ42 generation beginning from conception — explaining why carriers accumulate amyloid decades before symptoms appear and decades earlier than in sporadic Alzheimer's disease.

The Evidence

Houlden et al. 2001³³ Houlden et al. 2001
First description of PSEN1 M233V: onset approximately age 30, pathological examination showed extensive cortical Lewy bodies alongside plaques and tangles — an unusual combined neuropathology. Neurosci Lett. established that the M233V mutation produces "exceptionally early onset" disease, distinguishing it from typical sporadic AD (mean onset ~73 years) and even from most PSEN1 mutations (mean onset typically 40–55 years). Subsequent case reports have consistently replicated onset in the 25–32 year range.

A Chinese case series from Liu et al. 2019⁴⁴ Liu et al. 2019
Two de novo PSEN1 EOFAD cases; M233V patient had cognitive decline, parkinsonism, and epilepsy beginning at age 25. J Alzheimers Dis. documented a negative family history — confirming that de novo M233V mutations occur and must be considered in diagnostically challenging young-onset dementia even without a family history of the disease.

A 2021 multimodal neuroimaging study by Aghakhanyan et al.⁵⁵ Aghakhanyan et al.
31-year-old male with de novo M233V; simultaneous PET/MRI revealed widespread cortical amyloid (Thal stage III), hippocampal tau (Braak III/IV), structural atrophy, and disrupted functional connectivity. Curr Alzheimers Res. demonstrated that even in a single affected individual, the molecular, structural, and functional signatures of advanced Alzheimer's disease are fully established by age 31 — more than four decades earlier than typical disease.

Appel-Cresswell et al. 2018⁶⁶ Appel-Cresswell et al. 2018
Canadian-Vietnamese family with M233V; ataxia, parkinsonism, spasticity, dystonia, myoclonus, hallucinations, and behavioral changes alongside dementia. J Mov Disord. and Seliverstov et al. 2020⁷⁷ Seliverstov et al. 2020
M233V presenting as spinocerebellar ataxia-like syndrome at age 26; confirmed via Sanger sequencing after SCA panel was negative. Cerebellum. together demonstrate that M233V frequently presents with prominent extrapyramidal and cerebellar features — a phenotype broad enough that clinicians may pursue SCA or Parkinson workups before the correct diagnosis is reached.

Practical Actions

Because M233V is fully penetrant and autosomal dominant, every carrier will develop Alzheimer's disease if they live long enough. The genetic finding demands three parallel tracks of action:

Cognitive monitoring: Pre-symptomatic carriers should establish a baseline neuropsychological profile and consider enrolment in prevention trials. Longitudinal assessments allow detection of earliest cognitive changes (typically working memory and executive function decline) years before clinical diagnosis.

Family communication: First-degree relatives (parents, siblings, children) each have a 50% probability of carrying the same mutation. Cascade genetic testing — offered through clinical genetics or a specialist memory clinic — allows relatives to make informed decisions about whether they want to know their own status.

Prevention trial access: PSEN1 mutations are the most actively studied genetic target in Alzheimer's disease prevention research. Carriers should be informed about and offered referral to trials in the Dominantly Inherited Alzheimer Network (DIAN-TU) or similar prevention programmes that enrol pre-symptomatic carriers.

Interactions

PSEN1 interacts functionally with APOE genotype — APOE4 (rs7412/rs429358) accelerates amyloid deposition in PSEN1 mutation carriers. While the M233V mutation is dominant and fully penetrant regardless of APOE status, co-inheritance of APOE4 may influence the age of onset and the rate of amyloid accumulation. PSEN1 also interacts with APP (Amyloid Precursor Protein) variants — pathogenic APP mutations at the gamma-secretase cleavage site (e.g. rs63750447, rs63749810) may compound the Aβ42-elevating effect. These interactions should be assessed through comprehensive familial AD gene panels rather than single-SNP testing.

ALDH2 (aldehyde dehydrogenase 2) is the mitochondrial enzyme responsible for converting acetaldehyde to acetate during alcohol metabolism. Acetaldehyde is the toxic intermediate that causes many of the unpleasant effects of excessive drinking. The ALDH2*2 variant (rs671) is one of the most clinically significant pharmacogenomic variants known, primarily affecting East Asian populations where it reaches frequencies of 30-50%¹¹ 30-50%
Brooks PJ et al. The alcohol flushing response. PLoS Med, 2009.

The Mechanism

The rs671 variant causes a glutamic acid-to-lysine substitution at position 504²² Amino acid change: glutamic acid to lysine at position 504 (E504K) of the ALDH2 protein. This change occurs in the active site and has a dominant-negative effect³³ Dominant-negative: a single defective copy sabotages the protein complex even when a normal copy is present - even one copy of the *2 allele dramatically reduces enzyme activity because ALDH2 functions as a tetramer⁴⁴ A tetramer is a protein complex assembled from four subunits, and incorporating even one defective subunit impairs the entire complex. Heterozygous carriers retain only about 6% of normal activity, while homozygous carriers have essentially zero activity. This variant is classified as pathogenic by ClinVar⁵⁵ ClinVar
VCV000018390.

The Flush Reaction

When ALDH2 activity is impaired, acetaldehyde accumulates rapidly after drinking alcohol. This triggers the characteristic "Asian flush" or "alcohol flush reaction": facial flushing, rapid heartbeat, nausea, headache, and general discomfort. These symptoms are caused by acetaldehyde's direct toxic effects on blood vessels and tissues. The reaction is the body's warning that a carcinogenic compound is accumulating.

The Cancer Connection

The most serious consequence of ALDH2 deficiency is cancer risk. Acetaldehyde is classified as a Group 1 carcinogen⁶⁶ Group 1 carcinogen
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lancet Oncol, 2009 by the IARC⁷⁷ Group 1: sufficient evidence of carcinogenicity in humans, the highest IARC classification. Heterozygous carriers who drink regularly have a 6-10 fold increased risk of esophageal squamous cell carcinoma. This risk is so significant that the World Health Organization has identified ALDH2 deficiency combined with alcohol consumption as a major preventable cause of cancer in East Asia.

Nitroglycerin Interaction

ALDH2 is also involved in the bioactivation of nitroglycerin (glyceryl trinitrate), a medication used for angina chest pain. Li et al. showed⁸⁸ Li et al. showed
Li Y et al. ALDH2 bioactivation of nitroglycerin. Arterioscler Thromb Vasc Biol, 2006 that ALDH2*2 carriers had a reduced vasodilatory response to nitroglycerin, which could be clinically important during cardiac emergencies.

Practical Implications

If you carry the *2 allele, the flush reaction is not just an inconvenience - it is a cancer warning signal. The safest approach is to avoid or severely limit alcohol consumption. If you do not experience flushing (GG genotype), standard alcohol guidelines apply, though moderation remains advisable for overall health. Note that in European populations, this variant is extremely rare (less than 0.01%), while in East Asian populations it is the most common pharmacogenomic variant, affecting nearly 1 in 3 people.

CDHR3 (cadherin-related family member 3)¹¹ CDHR3 (cadherin-related family member 3)
A cell-surface adhesion molecule expressed exclusively on ciliated airway epithelial cells, including those lining the bronchi, trachea, nasopharynx, and middle ear is not just a structural protein — it is the receptor that rhinovirus-C (RV-C) uses to enter respiratory cells. RV-C is the most clinically severe of the three rhinovirus species, disproportionately responsible for childhood asthma exacerbations requiring hospitalization. The rs6967330 missense variant — a single nucleotide change that swaps cysteine for tyrosine at amino acid position 529 (C529Y) — dramatically alters how efficiently RV-C can dock onto and infect airway cells.

The tyrosine-529 form (the A allele, carried by roughly 17% of Europeans) makes CDHR3 a far more effective viral receptor: it localizes more densely on the cell surface and binds RV-C with approximately ten times the efficiency of the common cysteine-529 form. This variant exemplifies how a single amino acid difference can transform a structural protein into a viral susceptibility factor of substantial clinical significance.

The Mechanism

CDHR3 is expressed exclusively on ciliated airway epithelial cells²² ciliated airway epithelial cells
Ciliated cells line the respiratory tract and beat rhythmically to move mucus and trapped particles upward and out — they are also the primary entry point for RV-C. RV-C virions bind to the extracellular domain of CDHR3 (specifically the EC1 domain) as their obligate entry mechanism.

The C529Y substitution resides in the extracellular cadherin repeat region³³ extracellular cadherin repeat region
Cadherins use repeated structural domains (EC1–EC5) for binding; the EC1 domain is the virus contact surface identified by Watters & Palmenberg 2018 of the protein. The tyrosine at position 529 alters the protein's folding or glycosylation state in a way that increases its density at the apical cell surface. A landmark PNAS study found that cells transfected with the Y529 variant showed approximately 10-fold higher RV-C binding and progeny virus yields⁴⁴ landmark PNAS study found that cells transfected with the Y529 variant showed approximately 10-fold higher RV-C binding and progeny virus yields
Compared to cells expressing the common C529 form under identical infection conditions; the variant did not affect expression of other cadherin family members. Complementary knockout experiments confirmed that CDHR3 is the non-redundant entry receptor: eliminating CDHR3 expression reduced HRV-C infection of mucociliary epithelium by 80%⁵⁵ eliminating CDHR3 expression reduced HRV-C infection of mucociliary epithelium by 80%
Functional genomics study using airway organoids and CRISPR knockdown, published in JACI 2019.

Because CDHR3 is also expressed on ciliated epithelial cells lining the Eustachian tube⁶⁶ Eustachian tube
The channel connecting the nasopharynx to the middle ear — its ciliated lining is part of the same mucociliary apparatus that clears pathogens from the upper respiratory tract and middle ear, RV-C infections seeded by higher CDHR3-Y529 expression can ascend to trigger otitis media (middle ear infection) — explaining the multi-infection GWAS signals at this locus.

The Evidence

The strongest evidence comes from a GWAS of 1,173 children with recurrent severe asthma exacerbations and 2,522 controls, published in Nature Genetics⁷⁷ GWAS of 1,173 children with recurrent severe asthma exacerbations and 2,522 controls, published in Nature Genetics
Bønnelykke et al. 2014; phenotype specifically selected for early childhood asthma (ages 2–6) requiring emergency care — this phenotypic specificity may explain why the CDHR3 signal emerged when broader asthma GWAS missed it. The CDHR3 locus reached genome-wide significance, making it one of the top genetic determinants of severe childhood-onset asthma.

A 2025 pediatric study examining 297 rhinovirus-positive children found that carriers of the A allele (Y529) had nearly twice the risk of rhinovirus-C-induced wheezing compared to GG carriers⁸⁸ nearly twice the risk of rhinovirus-C-induced wheezing compared to GG carriers
OR 1.91, 95% CI 1.05–3.48, P = 0.033; dominant model; study of 129 HRV-C cases and 148 HRV-A controls from hospitalized children with acute respiratory infections. Notably, 56.67% of HRV-C-infected A-allele carriers experienced wheezing, versus a lower rate in GG carriers.

The connection to middle ear infections was established in a 2021 multi-ethnic family study showing that CDHR3 variants co-segregate with otitis media susceptibility in 257 families⁹⁹ CDHR3 variants co-segregate with otitis media susceptibility in 257 families
Exome sequencing of 407 US trios; the p.Cys529Tyr variant associated with altered middle ear microbiome and disease course. CDHR3 expression is present in ciliated middle ear epithelium and is downregulated following infection — consistent with viral exploitation of the receptor.

Mechanistically, recombinant EC1 domain fragments of CDHR3 competitively inhibit RV-C infection across multiple genotypes (C02, C15, C41, C45)¹⁰¹⁰ recombinant EC1 domain fragments of CDHR3 competitively inhibit RV-C infection across multiple genotypes (C02, C15, C41, C45)
Proof-of-concept for receptor-blocking as a therapeutic strategy; inhibitory fragments reduced infection across diverse RV-C strains in cell-based assays, confirming that CDHR3 is the non-redundant receptor and validating it as a potential therapeutic target.

Practical Actions

Carriers of the A allele (heterozygous AG or homozygous AA) have meaningfully higher risk of severe rhinovirus-C respiratory infections. Rhinovirus-C infections are not prevented by current influenza or COVID-19 vaccines — there is no licensed RV-C vaccine. The actionable strategy is reducing viral acquisition and supporting rapid immune clearance.

RV-C is transmitted primarily through direct contact (hands-to-face) and respiratory droplets. Hand hygiene is uniquely effective against rhinoviruses because, unlike influenza, rhinoviruses survive for hours on surfaces and are primarily acquired via hand-to-mucosa contact. This is a genotype-specific reason to be rigorous about hand hygiene during peak rhinovirus season (autumn and spring) — not generic advice, but a targeted risk-mitigation strategy for CDHR3-Y529 carriers who face ~10-fold higher cell-surface receptor availability.

For children with this variant who have recurrent wheezing, the CDHR3 genotype supports a clinical discussion about rhinovirus-C-triggered asthma phenotype and the potential role of early antiviral or anti-inflammatory intervention during respiratory infections. [Nasal zinc acetate lozenges | Zinc interferes with ICAM-1-mediated rhinovirus binding and has documented efficacy for rhinovirus infections, though data specific to RV-C are limited] have evidence for shortening rhinovirus illness duration.

Interactions

CDHR3-Y529 risk is compounded by co-inherited asthma susceptibility variants. The Bønnelykke GWAS also detected signals at GSDMB, IL33, and IL1RL1 — all operating through airway inflammatory pathways. Carriers of CDHR3 Y529 combined with IL33 or IL1RL1 risk variants face both heightened RV-C entry and amplified downstream inflammatory responses, potentially explaining the "two-hit" pattern of severe exacerbations in some children. The supervisor should consider a compound action for CDHR3 + IL33/IL1RL1 combinations if those SNPs are in the database.

BACE1¹¹ BACE1
beta-site amyloid precursor protein cleaving enzyme 1 is the enzyme that makes the first cut in amyloid precursor protein (APP), initiating the amyloidogenic cascade that produces amyloid-beta peptides. Without BACE1 activity, amyloid plaques — the pathological hallmark of Alzheimer's disease — cannot form. This makes BACE1 the rate-limiting step in amyloid production and one of the most intensively studied drug targets in neurodegenerative disease.

rs638405 is a synonymous variant in exon 5: the nucleotide changes from C to G, but the encoded amino acid remains valine (GTG→GTC). It lies within the BACE1 coding sequence on chromosome 11q23.3.

The Mechanism

Because rs638405 does not change the BACE1 protein sequence, any effect it exerts must be indirect — through altered mRNA splicing²² mRNA splicing
some synonymous variants affect splice site recognition or mRNA secondary structure even without amino acid changes, differential codon usage affecting translation efficiency, or linkage disequilibrium with an unidentified nearby regulatory variant. Sjölander et al. (2010) directly tested whether rs638405 genotype affects BACE1 enzymatic activity in CSF and found no measurable difference across genotypes, arguing against a direct catalytic effect. If the SNP has a biological consequence, it is likely through gene expression regulation rather than protein function.

The Evidence

Meta-analysis by Yu et al. (2016)³³ Meta-analysis by Yu et al. (2016)
"Meta-analysis of BACE1 gene rs638405 polymorphism and the risk of Alzheimer's disease in Caucasian and Asian population." Neurosci Lett, 2016. synthesized 13 case-control studies (2,538 AD patients, 3,020 controls) and found the G-allele homozygous genotype associated with ~22% elevated AD risk (OR=1.22, 95% CI 1.04–1.44, p=0.02 for GG vs CC). Under a recessive model the OR reached 1.25 (p=0.0008). Effects were somewhat stronger in Asian populations (GG vs CC OR=1.43, p=0.01).

Jo et al. (2008)⁴⁴ Jo et al. (2008)
"Association of BACE1 gene polymorphism with Alzheimer's disease in Asian populations." Dement Geriatr Cogn Disord, 2008. identified an important subgroup effect: although the overall association was weak, among APOE4 carriers the G-allele homozygous genotype carried an OR of approximately 2.0 for Alzheimer's disease (p=0.0044). This suggests the variant may amplify the already-elevated risk conferred by APOE4.

Wang et al. (2017)⁵⁵ Wang et al. (2017)
"Relationship between the polymorphism in exon 5 of BACE1 gene and Alzheimer's disease." Aging Clin Exp Res, 2017. — the larger meta-analysis of 20 studies — found no statistically significant overall association, though it did observe a protective signal in APOE4-positive and Asian subgroups after excluding studies deviating from Hardy-Weinberg equilibrium. The lack of an overall effect across a larger sample tempers enthusiasm.

Yin et al. (2025)⁶⁶ Yin et al. (2025)
"Genetic polymorphism in beta-site amyloid precursor protein-cleaving enzyme 1 affects the structure of medial temporal lobe and cognition in AD." Eur Arch Psychiatry Clin Neurosci, 2025. found that G-allele carriers among AD patients have significantly lower global cognition and memory scores, with reduced gray matter volume in the left parahippocampus and right hippocampus — regions critical to episodic memory encoding.

Overall, the evidence suggests a modest, inconsistent association primarily detectable in Asian populations and in APOE4 carriers. The effect size is small (OR ~1.2), the mechanism is unclear, and large meta-analyses disagree. This variant is best understood as a weak modulator, not a major Alzheimer's risk gene.

Practical Actions

The modest and inconsistent risk signal from rs638405 does not support aggressive intervention on its own. However, for individuals who also carry APOE4 — where the combined signal is stronger — there is value in proactively monitoring cognitive health and protecting cerebrovascular reserve. BACE1 activity depends on cholesterol homeostasis and endosomal pH; variants in the amyloid pathway interact meaningfully with lipid metabolism genetics. Monitoring APOE status and engaging APOE-specific neuroprotective strategies (detailed in the APOE rs429358 profile) is the highest-yield action for this SNP.

For GG carriers without APOE4, the small risk increment warrants periodic cognitive screening after age 60 but not major lifestyle disruption.

Interactions

The clearest interaction is with APOE4 (rs429358, rs7412). Jo et al. (2008) showed the GG genotype is essentially neutral in APOE4-negative individuals but roughly doubles Alzheimer's risk in APOE4 carriers — a gene-gene interaction suggesting BACE1 expression and APOE lipid biology converge on amyloid clearance. The proposed mechanism is that APOE4 impairs amyloid-beta clearance while BACE1 over-activity (potentially increased by the G-allele through unknown regulatory effects) increases amyloid-beta production — creating a dual hit on amyloid homeostasis.

rs3851179 (PICALM) and rs744373 (BIN1) are endocytic pathway SNPs that affect APP trafficking and amyloid-beta production and clearance; they share the broader amyloid/endosomal pathway with BACE1.

The DPYD gene encodes dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme responsible for metabolizing 80-90% of fluoropyrimidine chemotherapy drugs¹¹ 80-90% of fluoropyrimidine chemotherapy drugs
These include 5-fluorouracil (5-FU), capecitabine, and tegafur, among the most widely used cancer treatments worldwide. DPD breaks down these drugs into inactive metabolites, preventing toxic accumulation.

The D949V variant (c.2846A>T) is one of four decreased-function DPYD variants recommended for mandatory pre-treatment screening by the European Medicines Agency²² mandatory pre-treatment screening by the European Medicines Agency
The EMA mandates testing for DPD deficiency before fluoropyrimidine treatment in all cancer patients across Europe. and included in Clinical Pharmacogenetics Implementation Consortium (CPIC) Level 1A guidelines³³ Clinical Pharmacogenetics Implementation Consortium (CPIC) Level 1A guidelines
Level 1A is the highest evidence tier, indicating variant-specific prescribing guidance in clinical guidelines with strong supporting evidence.

The Mechanism

The D949V variant replaces aspartic acid with valine at codon 949 in the 4Fe-4S ferredoxin-type iron-sulfur binding domain⁴⁴ 4Fe-4S ferredoxin-type iron-sulfur binding domain
This domain is critical for the enzyme's catalytic activity. The aspartic acid residue is highly conserved across 100 vertebrate species. This is a non-conservative substitution — aspartic acid is a charged, polar amino acid while valine is hydrophobic and uncharged, creating substantial physicochemical disruption to protein structure⁵⁵ substantial physicochemical disruption to protein structure.

In vitro studies show the variant reduces DPD enzyme activity to 39-59% of wild-type when expressed in cell lines⁶⁶ In vitro studies show the variant reduces DPD enzyme activity to 39-59% of wild-type when expressed in cell lines
Studies by Offer et al. 2014 and van Kuilenburg et al. 2016 demonstrated this consistent reduction. In heterozygous carriers (one copy of the variant), DPD activity measured in peripheral blood mononuclear cells is reduced by approximately 30%⁷⁷ DPD activity measured in peripheral blood mononuclear cells is reduced by approximately 30%
This translates to a 40-80% reduction in 5-fluorouracil clearance.

The Evidence

A 2013 meta-analysis of 7,365 patients across eight cohort studies⁸⁸ A 2013 meta-analysis of 7,365 patients across eight cohort studies
Meulendijks et al. demonstrated carriers of c.2846A>T have a 3.0-fold increased risk (95% CI 2.2-4.1) of severe fluoropyrimidine toxicity. Severe toxicity includes life-threatening diarrhea, mucositis, bone marrow suppression, and hand-foot syndrome.

The prospective Alpe-DPD study (Henricks et al. 2018)⁹⁹ prospective Alpe-DPD study (Henricks et al. 2018)
This landmark Dutch multicenter study genotyped 1,181 patients before fluoropyrimidine treatment and adjusted doses based on genotype. demonstrated that pre-emptive genotyping with 50% dose reduction in heterozygous D949V carriers reduced severe toxicity rates to levels comparable to non-carriers. Initially, CPIC recommended 25-50% dose reduction for decreased-function variants like D949V, but updated this to a firm 50% reduction in November 2018¹⁰¹⁰ updated this to a firm 50% reduction in November 2018
The update was based on evidence that 25% reduction was insufficient to prevent toxicity in many carriers. following the Henricks study results.

Recent case reports of homozygous D949V carriers¹¹¹¹ Recent case reports of homozygous D949V carriers
Individuals with two copies of the variant have even more severely reduced DPD activity. indicate that >50% dose reduction may be necessary in this rare genotype, or alternative non-fluoropyrimidine chemotherapy should be considered.

The 2023 PhotoDPYD study of 8,054 Spanish cancer patients¹²¹² 2023 PhotoDPYD study of 8,054 Spanish cancer patients
This is the largest European assessment of DPYD variant frequencies to date. found c.2846A>T in 1.3% of patients (105 heterozygous carriers, 3 homozygous), making it the second most common clinically relevant DPYD variant after HapB3. The variant is found at similar frequencies (~0.6% allele frequency) across European populations¹³¹³ found at similar frequencies (~0.6% allele frequency) across European populations
gnomAD v4 reports 7,583 heterozygous and 29 homozygous carriers among 1,179,644 European alleles.

Practical Implications

If you have one copy of the D949V variant and require fluoropyrimidine chemotherapy, your oncologist should reduce the starting dose by 50% and carefully titrate upward based on tolerance. This approach maintains treatment efficacy while dramatically reducing the risk of severe toxicity. Pre-emptive DPYD screening has been shown to be cost-effective¹⁴¹⁴ Pre-emptive DPYD screening has been shown to be cost-effective
The cost of screening is offset by reduced hospitalizations for severe toxicity, which can exceed $180,000 per incident. and is now standard of care across much of Europe.

The four-variant DPYD panel (including D949V, DPYD*2A, DPYD*13, and HapB3) captures approximately 20-30% of patients who will experience severe fluoropyrimidine toxicity¹⁵¹⁵ approximately 20-30% of patients who will experience severe fluoropyrimidine toxicity
The remaining 70-80% of toxicity cases are due to other factors including rare DPYD variants, drug interactions, and non-genetic factors. This means that even with a normal result on this panel, careful monitoring during fluoropyrimidine treatment remains essential.

Interactions

The D949V variant is one of four clinically actionable DPYD variants that together define DPD metabolizer status. Compound heterozygosity — carrying D949V along with another decreased or no-function DPYD variant (rs3918290/DPYD*2A, rs55886062/DPYD*13, or rs75017182/HapB3) — results in poor metabolizer status with activity score of 1.0¹⁶¹⁶ poor metabolizer status with activity score of 1.0
The DPYD activity score system assigns 0.5 points per decreased-function allele and 0 points per no-function allele, with normal being 2.0. requiring even more aggressive dose reductions (typically ≥50% reduction with very gradual titration) or selection of alternative chemotherapy. Three compound heterozygous cases were documented in the PhotoDPYD study¹⁷¹⁷ Three compound heterozygous cases were documented in the PhotoDPYD study
Two carried DPYD*2A + c.2846A>T and two carried HapB3 + c.2846A>T. Such combinations dramatically increase toxicity risk and require specialized pharmacogenomic guidance.

The well-known rs7927894 T allele at chromosome 11q13.5 is one of the most replicated atopic dermatitis susceptibility signals in the human genome — but the full story of this locus requires a second variant. Ponińska et al. (2017)¹¹ Ponińska et al. (2017)
Ponińska et al., PLoS One 2017 — 2,437 participants from the ECAP (Epidemiology of Allergic Diseases in Poland) cohort including subjects with atopic dermatitis, atopic asthma, and persistent allergic rhinitis plus matched controls showed that the risk conferred by rs7927894 T is not carried by the T allele alone: it is haplotype-dependent, and specifically requires the G allele at rs7125552 to manifest. Without G at this position, the rs7927894 T allele's association with atopic dermatitis and allergic rhinitis disappears.

This kind of haplotype dependency is clinically meaningful: it means that genotyping rs7927894 alone gives an incomplete picture of this locus's risk contribution. rs7125552 is the contextual marker that defines whether the risk haplotype is complete.

The Mechanism

rs7125552 sits at position 76,500,050 on chromosome 11 (GRCh38, NC_000011.10:g.76500050G>A), approximately 90 kilobases upstream of rs7927894 (position 76,590,272) within the EMSY gene body. Both variants lie within the same topologically associating domain (TAD) that encompasses EMSY and LRRC32²² EMSY and LRRC32
EMSY (C11orf30) is a chromatin regulatory protein that epigenetically suppresses skin barrier genes including filaggrin and ceramide synthesis enzymes; LRRC32 encodes GARP, a TGF-β receptor complex component on regulatory T cells — both genes contribute to allergic susceptibility through distinct mechanisms at the same genomic address.

The intronic location of rs7125552 within EMSY suggests it acts as a regulatory element — likely a cis-regulatory variant that interacts with the rs7927894 regulatory signal to form the complete functional haplotype. Neither variant alone captures the full effect; together, they define a chromatin state in which EMSY expression is maximally elevated. Higher EMSY activity epigenetically silences filaggrin, filaggrin-2, and long-chain ceramide synthesis enzymes — the proteins that build and maintain the skin's physical barrier against allergen entry and water loss. The resulting barrier deficit is the upstream event that permits allergen sensitisation and initiates the atopic march.

The Evidence

The Ponińska et al. haplotype analysis across 2,437 ECAP cohort participants is the key evidence for this variant's role. In single-SNP analysis, rs7125552 showed no significant independent association with atopic dermatitis (OR=1.08, p=0.49). Its importance emerges at the haplotype level: the TG haplotype (T at rs7927894, G at rs7125552) carried an OR of 1.92 (p=0.00021) for atopic dermatitis and OR=1.32 (p=0.023) for persistent allergic rhinitis. In contrast, the TA haplotype (T at rs7927894, A at rs7125552) had OR=1.12 (p=0.36) — statistically indistinguishable from no effect. This demonstrates that rs7125552 G is not merely a passenger — it is structurally required for the allergy risk haplotype to be functional.

The 11q13.5 locus was confirmed as a key atopic march locus in a 2015 meta-analysis³³ 2015 meta-analysis
Marenholz et al., Nat Commun 2015 — 12 populations, 2,428 combined eczema+asthma cases and 17,034 controls and in the large Paternoster et al. meta-GWAS⁴⁴ Paternoster et al. meta-GWAS
Nat Genet 2011 — 5,606 cases and 20,565 controls in discovery; 5,419 and 19,833 in replication. These studies replicate the 11q13.5 association; the Ponińska work adds the mechanistic detail that the haplotype — not a single SNP — is the functional unit.

The mechanistic basis for why this haplotype matters was established by Elias and Brown (2019)⁵⁵ Elias and Brown (2019)
J Allergy Clin Immunol — siRNA knockdown and overexpression in organotypic skin models, plus proteomics and lipid analysis, plus AD biopsy immunohistochemistry: EMSY knockdown enhances barrier gene expression (filaggrin, filaggrin-2, long-chain ceramides), while EMSY overexpression suppresses these markers. AD skin biopsies show elevated nuclear EMSY staining, consistent with the risk haplotype driving excessive transcriptional repression of barrier genes.

Practical Actions

The actionable implications of rs7125552 mirror those of its haplotype partner rs7927894, because the two variants define the same functional unit. Carriers of G at rs7125552 who also carry T at rs7927894 are on the complete high-risk haplotype (TG), with an approximately twofold increased risk for atopic dermatitis. The primary intervention targets the EMSY-mediated barrier deficit: ceramide-containing emollient as proactive barrier support, avoidance of detergents that strip ceramides, and surveillance for atopic march progression (eczema → food allergy → respiratory allergy).

Carriers of AA at rs7125552 represent the minority (approximately 9%) who carry two copies of the haplotype-breaking A allele — these individuals appear protected from the rs7927894 T risk effect even if they carry T alleles at that position.

Interactions

The central interaction is the cis-haplotype with rs7927894: these two variants at 11q13.5 are best interpreted as a functional unit rather than as independent signals. The high-risk haplotype is T (rs7927894) + G (rs7125552); the protective configuration requires A at rs7125552.

Beyond the cis interaction, the 11q13.5 locus interacts with filaggrin loss-of-function variants (rs61816766 and rs12123821) through converging effects on skin barrier integrity. In paediatric cohorts, carrying both the 11q13.5 risk haplotype and a filaggrin null mutation raised atopic dermatitis odds to OR=16.41 — far beyond either variant alone. The IL13 variant rs20541 operates from the immune activation side of the same atopic phenotype and compounds the total risk carried by 11q13.5 haplotype carriers.

In 2006, the first genome-wide association study of episodic memory in healthy adults identified two genes linked to how well people remember verbal information. The first, KIBRA, became famous. The second, CLSTN2¹¹ CLSTN2
Calsyntenin-2 (calsyntenin 2), a postsynaptic transmembrane protein of the cadherin superfamily expressed exclusively in brain tissue, received less attention — but has since accumulated its own evidence base connecting it to memory circuits, inhibitory neuron integrity, and the hippocampus²² hippocampus
The seahorse-shaped brain structure critical for forming and retrieving episodic memories — the kind tied to specific events and experiences.

The Mechanism

CLSTN2 encodes a 955-amino-acid protein with two cadherin repeats³³ cadherin repeats
Structural domains that mediate calcium-dependent cell-cell adhesion; in neurons they help organize the postsynaptic density at synaptic junctions, a transmembrane domain, and a cytoplasmic tail. It is expressed exclusively in neural tissue, concentrated in the postsynaptic specializations of excitatory synapses — particularly in layers 5 and 6 of the cerebral cortex and throughout the hippocampus. Despite its location at excitatory synapses, calsyntenin-2 appears to exert its primary cognitive influence through a different circuit: it is required for the maintenance of inhibitory interneurons.

Mouse knockout studies⁴⁴ Mouse knockout studies
Lipina TV et al. Cognitive Deficits in Calsyntenin-2-deficient Mice Associated with Reduced GABAergic Transmission. Neuropsychopharmacology, 2016 showed that complete loss of CLSTN2 reduced the density of parvalbumin-positive GABAergic interneurons⁵⁵ parvalbumin-positive GABAergic interneurons
Fast-spiking inhibitory neurons that generate gamma-frequency oscillations (30-80 Hz) essential for encoding and retrieving episodic memories; they coordinate excitatory pyramidal cell firing with millisecond precision in hippocampal CA1, CA3, and dentate gyrus by 25-56%, with no effect on other interneuron subtypes (somatostatin, calretinin, calbindin). The result was a selective reduction in inhibitory postsynaptic currents and impaired spatial memory on the Morris water maze — while excitatory transmission and non-spatial cognition remained intact. The SNP rs6439886 sits in the first intron and does not alter the protein sequence directly; it is presumed to influence CLSTN2 expression in hippocampal tissue, though the exact regulatory mechanism has not been fully characterized.

The Evidence

The original GWAS⁶⁶ original GWAS
Papassotiropoulos A et al. Common Kibra alleles are associated with human memory performance. Science, 2006 screened over 500,000 SNPs in 351 young Swiss adults and identified rs6439886 as one of two loci associated with the best verbal episodic memory performers (the other being KIBRA rs17070145). Carriers of the G allele — described as the C allele in coding-strand notation — outperformed AA homozygotes on delayed free recall. Unlike the KIBRA finding, the CLSTN2 association was not replicated in the American cohort within the same study, suggesting possible population differences or age-dependence.

Subsequent independent studies have supported and extended the finding. A study in 383 healthy young adults⁷⁷ study in 383 healthy young adults
Preuschhof C et al. KIBRA and CLSTN2 polymorphisms exert interactive effects on human episodic memory. Neuropsychologia, 2010 found that CLSTN2 and KIBRA genotypes interact: the G allele of CLSTN2 positively modulates memory performance in people who also carry the KIBRA T allele. In KIBRA CC homozygotes, the CLSTN2 G allele provided no benefit or was slightly detrimental, suggesting the two genes converge on shared synaptic plasticity pathways.

In adolescents, a neuroimaging study⁸⁸ neuroimaging study
Jacobsen LK et al. Allelic variation of calsyntenin 2 (CLSTN2) modulates the impact of developmental tobacco smoke exposure on mnemonic processing in adolescents. Biological Psychiatry, 2009 confirmed a beneficial effect of the G allele on verbal recall and showed that this advantage is associated with enhanced functional connectivity between memory-related brain regions. Crucially, developmental tobacco smoke exposure eliminated the memory benefit and reversed the connectivity advantage in G carriers — making this one of the first demonstrations that a genetic memory advantage can be cancelled by environmental exposure during a sensitive developmental period.

In older adults with unipolar depression, a study of 2,170 people aged 60+⁹⁹ a study of 2,170 people aged 60+
Pantzar A et al. Interactive effects of KIBRA and CLSTN2 polymorphisms on episodic memory in old-age unipolar depression. Neuropsychologia, 2014 found that the combination of KIBRA CC and CLSTN2 AA genotypes was specifically associated with the lowest episodic memory performance among depressed individuals. Genetic effects on cognition appear to be amplified in populations with suboptimal cognitive reserve. A polygenic analysis of 2,490 dementia-free older adults¹⁰¹⁰ polygenic analysis of 2,490 dementia-free older adults
Laukka EJ et al. Combined genetic influences on episodic memory decline in older adults without dementia. Neuropsychology, 2020 found that a composite score including APOE, BDNF, KIBRA, and CLSTN2 risk alleles predicted faster episodic memory decline (β=-0.064, p<0.01), though CLSTN2 alone was not significant in that cohort.

Practical Implications

The actionable picture for AA homozygotes — the most common genotype — is one of modest increased vulnerability to episodic memory decline over time, particularly in conjunction with other memory-related variants and in the presence of environmental stressors. The CLSTN2 mechanism points specifically toward GABAergic interneuron health and synaptic inhibitory-excitatory balance in the hippocampus. Strategies that support parvalbumin interneuron function, promote hippocampal neuroplasticity, and protect against age-related inhibitory circuit loss are the most mechanistically coherent interventions.

Phosphatidylserine is one of the few supplements with reasonable clinical trial evidence for verbal memory support in older adults, with double-blind placebo-controlled data showing improvement in delayed verbal recall in people with subjective memory complaints. Its mechanism — supporting neuronal membrane integrity and signaling — is complementary to CLSTN2's role in maintaining synaptic scaffolding.

Importantly, the tobacco smoke reversal of the G allele memory benefit is a reminder that genetic advantages are not immune to environmental damage, particularly during development.

Interactions

The interaction between CLSTN2 rs6439886 and KIBRA rs17070145 is well documented. The memory-enhancing effect of the CLSTN2 G allele is contingent on the KIBRA T allele being present; in KIBRA CC homozygotes, CLSTN2 G provides no benefit and may be mildly detrimental. Both proteins operate in hippocampal synaptic plasticity pathways — KIBRA through PKMzeta-mediated long-term potentiation, CLSTN2 through maintenance of parvalbumin interneuron density. The combination of KIBRA CC and CLSTN2 AA (both risk-direction genotypes) is associated with the lowest episodic memory performance in studies of older adults with depression. This interaction is a candidate for a compound action: individuals carrying both KIBRA CC and CLSTN2 AA genotypes face additive risk and may benefit from more aggressive memory-supportive strategies than either variant alone would suggest.

CYP3A4 is the dominant drug-metabolizing enzyme in the human liver and intestine, processing approximately half of all prescription medications¹¹ approximately half of all prescription medications
Including statins, immunosuppressants, benzodiazepines, calcium channel blockers, HIV antiretrovirals, antifungals, and many anticancer agents. The CYP3A4*11 allele, defined by rs67784355 (c.1088C>T on the coding strand; p.Thr363Met), is one of the rarest functionally characterized CYP3A4 variants — but when it occurs, it produces a measurably compromised enzyme.

Threonine at position 363 sits within the substrate recognition site 5 (SRS-5)²² substrate recognition site 5 (SRS-5)
One of six substrate-recognition sites lining the CYP3A4 active site; SRS-5 contributes to the hydrogen-bonding network that stabilizes the active site architecture and positions substrates for catalysis. Replacing this threonine with a bulkier methionine disturbs the local protein structure, reducing both how much enzyme is produced and how stable it is once made.

The Mechanism

CYP3A4 is encoded on the minus (antisense) strand of chromosome 7. The *11 allele introduces a C→T change at position 1088 of the coding sequence (NM_017460.6:c.1088C>T), which on the genomic plus strand corresponds to a G→A substitution at rs67784355. The encoded threonine (polar, hydroxyl side chain) at codon 363 is replaced by methionine (hydrophobic, larger side chain). This is not a conservative substitution — methionine cannot fulfill the hydrogen-bonding role of threonine in the SRS-5 network.

In vitro expression studies³³ In vitro expression studies
Using baculovirus-insect cell and mammalian expression systems to produce recombinant CYP3A4 protein consistently find that CYP3A4*11 produces substantially less functional apoprotein than wild-type CYP3A4*1. The carbon monoxide-difference spectra⁴⁴ carbon monoxide-difference spectra
A spectrophotometric test of functional CYP content that measures correctly folded heme-containing protein of *11-expressing cells show reduced signal — meaning fewer active enzyme molecules, not just impaired ones.

The Evidence

Four independent in vitro studies characterize CYP3A4*11 across different substrates:

Loperamide: Wang et al. (2019)⁵⁵ Wang et al. (2019)
Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro found that CYP3A4*11's intrinsic clearance (CLint) for N-demethylation of loperamide was approximately 5.7-fold lower than wild-type, placing it among the most functionally impaired alleles tested. The authors attributed the deficit to protein instability from the bulky methionine substitution disrupting the tertiary structure at position 363.

Quinine: Gao et al. (2019)⁶⁶ Gao et al. (2019)
Enzymatic activities of CYP3A4 allelic variants on quinine 3-hydroxylation in vitro showed that CYP3A4*11 expressed at particularly low apoprotein levels compared to wild-type, consistent with reduced protein stability, and displayed reduced quinine hydroxylation activity. Five variants in total showed this pattern of low expression — *11 was among the most severely affected.

Midazolam and testosterone: Kato et al. (2021)⁷⁷ Kato et al. (2021)
Functional characterization of 40 CYP3A4 variants by assessing midazolam 1'-hydroxylation and testosterone 6β-hydroxylation confirmed reduced T363M expression in mammalian cells, noting that this substitution affects either protein expression or stability. The kinetic analysis placed *11 among the variants with meaningfully reduced catalytic efficiency.

Original identification: Sata et al. (2000)⁸⁸ Sata et al. (2000)
CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12 first identified *11 from human liver samples and demonstrated its altered catalytic activity, establishing residue 363 as functionally important.

The limitation of all current evidence is that it is exclusively in vitro. The 2023 joint consensus genotyping recommendation⁹⁹ 2023 joint consensus genotyping recommendation
From AMP, CPIC, CAP, DPWG, ESPT, and PharmGKB explicitly excluded CYP3A4*11 from its Tier 1 and Tier 2 clinical assay recommendations because of this limitation — no pharmacokinetic studies in human carriers have been published. The variant is too rare to recruit sufficient carriers for in vivo trials under normal circumstances.

Practical Implications

Because clinical pharmacokinetic data are absent, prescribers cannot rely on published dosing guidelines for *11 carriers as they can for CYP3A4*22 or CYP3A5*1/*3. However, the consistent direction of the in vitro evidence — reduced enzyme levels, reduced clearance across multiple chemically distinct substrates — makes it reasonable to apply the same precautions used for other CYP3A4 reduced-function alleles.

The drugs of greatest concern are those with narrow therapeutic windows metabolized primarily by CYP3A4: tacrolimus and cyclosporine (transplant immunosuppressants), statins particularly atorvastatin and simvastatin, midazolam and other benzodiazepines, and cardiotoxic drugs like loperamide (at high doses). For each of these, standard doses may produce higher-than-expected plasma concentrations in *11 carriers.

Importantly, CYP3A4 inhibitors (grapefruit, clarithromycin, ketoconazole, ritonavir) compound an already-reduced enzyme capacity — the additive effect of genetic reduction plus pharmacological inhibition can push drug levels into the toxic range.

Interactions

CYP3A4*11 exists in the same genetic neighborhood as the more common and better-studied CYP3A4 variants. The CYP3A4*22 allele (rs35599367)¹⁰¹⁰ CYP3A4*22 allele (rs35599367)
An intronic splice variant causing ~50% reduced CYP3A4 mRNA, with established clinical guidelines for tacrolimus dosing is the most clinically relevant partner. CYP3A4*38 was defined precisely because rs67784355 was found in cis with the CYP3A4*3-defining variant in some haplotypes, meaning the same chromosome can carry multiple reduced-function alleles simultaneously.

CYP3A5 status (rs776746) is critical context for CYP3A4*11 carriers. CYP3A5 is a closely related enzyme that partially compensates for reduced CYP3A4 activity. If a *11 carrier is also a CYP3A5 non-expresser (*3/*3, the case for ~85% of Europeans), total CYP3A enzyme capacity is substantially diminished. A CYP3A5 expresser who carries *11 may show near-normal overall CYP3A clearance because CYP3A5 compensates — the opposite is true in non-expressers.

Gene-drug interactions are equally important. Strong CYP3A4 inhibitors added to an already-impaired metabolizer create additive metabolic suppression. Any patient carrying CYP3A4*11 who starts an azole antifungal, macrolide antibiotic, or ritonavir-boosted HIV regimen while on a narrow-therapeutic-index CYP3A4 substrate should be monitored intensively.

On chromosome 11q13.5 sits a stretch of regulatory DNA that, in people carrying the G allele at rs7130588, subtly tips the balance of the immune system toward allergic reactivity. The gene controlled by this region, LRRC32, encodes GARP (Glycoprotein A Repetitions Predominant)¹¹ GARP (Glycoprotein A Repetitions Predominant)
GARP is a surface receptor expressed on activated regulatory T cells (Tregs); it docks latent TGF-β on the Treg cell surface, where TGF-β can be released in a controlled fashion to suppress nearby immune cells — a critical molecule in the suppressive machinery of regulatory T cells (Tregs). When GARP function is altered, the Treg-mediated braking on allergic inflammation weakens, and atopic diseases become more likely.

The Mechanism

GARP is a transmembrane receptor expressed exclusively on activated Tregs (and platelets). Its core job is to anchor the latent TGF-β1 complex — the "sleeping" form of this immunosuppressive cytokine — on the cell surface. Surface-tethered latent TGF-β can be activated locally, delivering targeted suppression to nearby effector T cells, dendritic cells, and B cells without flooding systemic circulation with active TGF-β. This spatial precision is what makes GARP-mediated tolerance so important: it allows Tregs to dampen Th2-skewed responses in peripheral tissues like the airway and skin while leaving systemic immunity intact.

rs7130588 lies in a regulatory (non-coding) region approximately 10 kb upstream of the LRRC32 promoter. A closely linked causal candidate, rs6592645 (in complete linkage disequilibrium with rs7130588), falls within an enhancer element that physically loops to the LRRC32 promoter. Luciferase reporter assays²² Luciferase reporter assays
A standard lab test where the regulatory region controls a bioluminescent reporter gene; more light = more transcriptional activity from that sequence confirmed that the A allele of rs6592645 (the rs7130588-G-linked haplotype) drives higher enhancer activity than the G allele, via preferential binding of the transcription factor TCF3. LRRC32 mRNA levels are correspondingly elevated in lung tissue of asthma patients in a genotype-dependent manner.

The counterintuitive implication: higher GARP expression might be expected to enhance Treg suppression and protect against allergy. The biology, however, is more complex. Elevated GARP may alter the balance between membrane-bound and soluble GARP isoforms, the ratio of latent-to-active TGF-β at the Treg surface, or Treg activation thresholds in ways that impair rather than enhance tolerance in allergic tissue contexts. The net clinical observation is unambiguous: the G-risk allele associates with more atopic disease, not less.

The Evidence

The sentinel discovery came from Ferreira et al. in the Lancet³³ Ferreira et al. in the Lancet
Australian Asthma Genetics Consortium GWAS, 57,800 participants including 2,669 asthmatics and 4,528 controls in the discovery stage plus 25,358 in replication (2011): rs7130588 reached genome-wide significance (OR 1.09, p=1.8×10⁻⁸) for overall asthma, with a stronger signal for atopic asthma specifically (OR 1.33 for atopic status among asthmatics, p=7×10⁻⁴). The authors concluded the locus "directly increases the risk of allergic sensitisation which, in turn, increases the risk of subsequent development of asthma."

The GWAS Catalog records two subsequent associations at this variant: OR 1.29 (95% CI 1.20–1.38, p=4×10⁻¹³) and OR 1.242 (95% CI 1.17–1.31, p=2×10⁻⁹) in larger replication efforts, confirming and strengthening the original signal.

Beyond asthma, the LRRC32 locus is a shared risk locus across the atopic triad. Weidinger et al.⁴⁴ Weidinger et al.
GWAS of childhood atopic dermatitis, 1,563 European cases and 4,054 controls with replication in a second cohort (2,286 cases, 3,160 controls) (2013) confirmed the proximal LRRC32 region at genome-wide significance for atopic dermatitis. Most tellingly, Marenholz et al.⁵⁵ Marenholz et al.
Meta-analysis of 12 populations, 2,428 cases of the "atopic march" phenotype (eczema followed by asthma), 17,034 controls (2015) confirmed LRRC32/C11orf30 as one of seven loci driving the progression from infantile eczema to childhood asthma — the classic atopic march. The locus sits at the intersection of all three major atopic phenotypes: eczema, allergic asthma, and (via the atopic march pathway) allergic rhinitis.

The functional direction — that GARP is genuinely causal, not just a passenger — is supported by a humanized mouse model study⁶⁶ humanized mouse model study
Mice engrafted with human PBMCs from birch-pollen sensitized donors; treatment with soluble GARP reduced airway hyperresponsiveness, neutrophil and macrophage influx, and mucus-producing goblet cells; effect abolished by anti-TGF-βRII antibody in which exogenous soluble GARP reduced allergic airway inflammation in a TGF-β receptor-dependent manner. Separately, a clinical study found that children who outgrow food allergy have significantly higher GARP expression on peripheral blood mononuclear cells compared with those who do not (p=0.005), establishing GARP as a marker — and potentially a driver — of immune tolerance acquisition.

Practical Actions

The G allele's risk is primarily expressed in the context of atopic sensitization. G-allele carriers who already have one atopic condition (eczema, food allergy, or allergic rhinitis) face meaningfully elevated risk of asthma development — the atopic march phenotype. Early allergist evaluation and proactive management of existing atopic conditions can interrupt this progression. Aeroallergen immunotherapy, which directly raises functional Treg activity and GARP expression, is the intervention most biologically aligned with this locus's mechanism.

For GG homozygotes (approximately 11% of people of European descent), the cumulative risk elevation is additive and warrants baseline spirometry and exhaled nitric oxide (FeNO) measurement to detect subclinical airway inflammation before clinical asthma develops.

Interactions

The LRRC32 locus partially overlaps with C11orf30 (EMSY), which is itself an independent asthma and eczema risk gene; fine-mapping distinguishes the two signals, but in population data they travel together on 11q13. rs6592645, the likely causal variant in full LD with rs7130588, is the preferred candidate for functional follow-up. rs3781700 (nearby in this region) has been identified with OR ~1.054 for atopic dermatitis in large GWAS, representing additional independent variation at the locus.

Compound effects with PTPN22 rs2476601 (R620W), a T-cell activation threshold variant, are plausible given both genes influence regulatory T cell function, but no formal gene-gene interaction study has yet been published.